{"id":63115,"date":"2026-04-14T20:34:29","date_gmt":"2026-04-14T12:34:29","guid":{"rendered":"https:\/\/flcube.com\/?p=63115"},"modified":"2026-04-14T20:34:30","modified_gmt":"2026-04-14T12:34:30","slug":"olymvax-biopharmaceuticals-and-westlake-university-launch-universal-influenza-vaccine-collaboration","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63115","title":{"rendered":"Olymvax Biopharmaceuticals and Westlake University Launch Universal Influenza Vaccine Collaboration"},"content":{"rendered":"\n<p><strong>Olymvax Biopharmaceuticals Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688319:SHA\">SHA: 688319<\/a>), the Chengdu-based vaccine specialist, announced a <strong>strategic partnership agreement<\/strong> with <strong>Westlake University<\/strong>, China&#8217;s first modern private research-oriented university, to jointly advance <strong>early-stage R&amp;D<\/strong> of a <strong>broad-spectrum (universal) influenza vaccine<\/strong>. The collaboration integrates Westlake&#8217;s <strong>basic scientific research capabilities<\/strong> with Olymvax&#8217;s <strong>mature vaccine industrialization experience<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-framework\">Partnership Framework<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Industry Partner<\/strong><\/td><td>Olymvax Biopharmaceuticals Inc. (SHA: 688319)<\/td><\/tr><tr><td><strong>Academic Partner<\/strong><\/td><td>Westlake University \u2013 Center for Infectious Disease Research<\/td><\/tr><tr><td><strong>Focus Area<\/strong><\/td><td>Early-stage R&amp;D of broad-spectrum (universal) influenza vaccine<\/td><\/tr><tr><td><strong>Collaboration Model<\/strong><\/td><td>Industry-university-research strategic partnership<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Preclinical\/early discovery phase<\/td><\/tr><tr><td><strong>Strategic Context<\/strong><\/td><td>Part of Olymvax&#8217;s &#8220;independent R&amp;D + collaborative R&amp;D&#8221; dual-driven approach<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-institutional-capabilities\">Institutional Capabilities<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-westlake-university-strengths\">Westlake University Strengths<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Research Foundation:<\/strong> Solid scientific research capabilities in infectious disease and influenza vaccine development<\/li>\n\n\n\n<li><strong>Institutional Profile:<\/strong> China&#8217;s first modern private research-oriented university with aspirations to become globally competitive<\/li>\n\n\n\n<li><strong>Specialized Expertise:<\/strong> Center for Infectious Disease Research provides cutting-edge basic science infrastructure<\/li>\n\n\n\n<li><strong>Innovation Focus:<\/strong> Emphasis on breakthrough research addressing fundamental scientific challenges<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-olymvax-biopharmaceuticals-assets\">Olymvax Biopharmaceuticals Assets<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Industrial Experience:<\/strong> Mature vaccine development and manufacturing capabilities<\/li>\n\n\n\n<li><strong>Translation Expertise:<\/strong> Proven track record in converting basic research into commercial vaccine products<\/li>\n\n\n\n<li><strong>Strategic Approach:<\/strong> Dual-driven R&amp;D model combining internal innovation with external partnerships<\/li>\n\n\n\n<li><strong>Market Orientation:<\/strong> Focus on developing commercially viable vaccine solutions with global potential<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-collaboration-mechanisms\">Collaboration Mechanisms<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Coordinated R&amp;D Framework:<\/strong> Structured joint development process with clear milestone tracking<\/li>\n\n\n\n<li><strong>Information Sharing Protocol:<\/strong> Transparent data exchange and intellectual property management<\/li>\n\n\n\n<li><strong>Synergy Optimization:<\/strong> Leveraging complementary strengths across the innovation value chain<\/li>\n\n\n\n<li><strong>Technical Focus:<\/strong> Addressing existing bottlenecks in universal influenza vaccine development through novel approaches<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-significance\">Strategic Significance<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Universal Influenza Market:<\/strong> Addresses $5+ billion annual seasonal influenza vaccine market with potential for premium pricing and broader protection<\/li>\n\n\n\n<li><strong>Technical Innovation:<\/strong> Aims to overcome limitations of current strain-specific vaccines requiring annual reformulation<\/li>\n\n\n\n<li><strong>China Innovation Ecosystem:<\/strong> Represents successful industry-academia collaboration model in China&#8217;s evolving biopharmaceutical landscape<\/li>\n\n\n\n<li><strong>Global Competitiveness:<\/strong> Positions Chinese entities in race for universal influenza vaccine alongside international competitors including NIH, Moderna, and GSK<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-objectives\">Development Objectives<\/h2>\n\n\n\n<p>The partnership specifically targets the development of a <strong>novel influenza vaccine with broad protective coverage<\/strong> capable of:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Providing long-lasting immunity against multiple influenza strains<\/li>\n\n\n\n<li>Reducing or eliminating need for annual vaccination<\/li>\n\n\n\n<li>Overcoming antigenic drift and shift challenges of current vaccines<\/li>\n\n\n\n<li>Establishing foundation for pandemic preparedness<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-terms\">Financial Terms<\/h2>\n\n\n\n<p>Specific financial terms of the collaboration were not disclosed. The agreement establishes a framework for shared investment in early-stage research with potential future milestone payments and royalty arrangements based on development success.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding research collaboration, development objectives, and strategic expectations for the universal influenza vaccine program. Actual results may differ due to risks inherent in vaccine development, including scientific feasibility, technical challenges, regulatory pathways, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Olymvax Biopharmaceuticals Inc. (SHA: 688319), the Chengdu-based vaccine specialist, announced a strategic partnership agreement with&#8230;<\/p>\n","protected":false},"author":1,"featured_media":63116,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[702,1402,12],"class_list":["post-63115","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-olymvax-biopharmaceuticals","tag-sha-688319","tag-vaccine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Olymvax Biopharmaceuticals and Westlake University Launch Universal Influenza Vaccine Collaboration - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Olymvax Biopharmaceuticals Inc. (SHA: 688319), the Chengdu-based vaccine specialist, announced a strategic partnership agreement with Westlake University, China&#039;s first modern private research-oriented university, to jointly advance early-stage R&amp;D of a broad-spectrum (universal) influenza vaccine. The collaboration integrates Westlake&#039;s basic scientific research capabilities with Olymvax&#039;s mature vaccine industrialization experience.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63115\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Olymvax Biopharmaceuticals and Westlake University Launch Universal Influenza Vaccine Collaboration\" \/>\n<meta property=\"og:description\" content=\"Olymvax Biopharmaceuticals Inc. (SHA: 688319), the Chengdu-based vaccine specialist, announced a strategic partnership agreement with Westlake University, China&#039;s first modern private research-oriented university, to jointly advance early-stage R&amp;D of a broad-spectrum (universal) influenza vaccine. The collaboration integrates Westlake&#039;s basic scientific research capabilities with Olymvax&#039;s mature vaccine industrialization experience.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63115\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-14T12:34:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-14T12:34:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1402-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63115#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63115\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Olymvax Biopharmaceuticals and Westlake University Launch Universal Influenza Vaccine Collaboration\",\"datePublished\":\"2026-04-14T12:34:29+00:00\",\"dateModified\":\"2026-04-14T12:34:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63115\"},\"wordCount\":465,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63115#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1402-1.webp\",\"keywords\":[\"Olymvax Biopharmaceuticals\",\"SHA: 688319\",\"Vaccine\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63115#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63115\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63115\",\"name\":\"Olymvax Biopharmaceuticals and Westlake University Launch Universal Influenza Vaccine Collaboration - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63115#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63115#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1402-1.webp\",\"datePublished\":\"2026-04-14T12:34:29+00:00\",\"dateModified\":\"2026-04-14T12:34:30+00:00\",\"description\":\"Olymvax Biopharmaceuticals Inc. (SHA: 688319), the Chengdu-based vaccine specialist, announced a strategic partnership agreement with Westlake University, China's first modern private research-oriented university, to jointly advance early-stage R&D of a broad-spectrum (universal) influenza vaccine. The collaboration integrates Westlake's basic scientific research capabilities with Olymvax's mature vaccine industrialization experience.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63115#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63115\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63115#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1402-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1402-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Olymvax Biopharmaceuticals and Westlake University Launch Universal Influenza Vaccine Collaboration\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63115#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Olymvax Biopharmaceuticals and Westlake University Launch Universal Influenza Vaccine Collaboration\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Olymvax Biopharmaceuticals and Westlake University Launch Universal Influenza Vaccine Collaboration - Insight, China&#039;s Pharmaceutical Industry","description":"Olymvax Biopharmaceuticals Inc. (SHA: 688319), the Chengdu-based vaccine specialist, announced a strategic partnership agreement with Westlake University, China's first modern private research-oriented university, to jointly advance early-stage R&D of a broad-spectrum (universal) influenza vaccine. The collaboration integrates Westlake's basic scientific research capabilities with Olymvax's mature vaccine industrialization experience.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63115","og_locale":"en_US","og_type":"article","og_title":"Olymvax Biopharmaceuticals and Westlake University Launch Universal Influenza Vaccine Collaboration","og_description":"Olymvax Biopharmaceuticals Inc. (SHA: 688319), the Chengdu-based vaccine specialist, announced a strategic partnership agreement with Westlake University, China's first modern private research-oriented university, to jointly advance early-stage R&D of a broad-spectrum (universal) influenza vaccine. The collaboration integrates Westlake's basic scientific research capabilities with Olymvax's mature vaccine industrialization experience.","og_url":"https:\/\/flcube.com\/?p=63115","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-14T12:34:29+00:00","article_modified_time":"2026-04-14T12:34:30+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1402-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63115#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63115"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Olymvax Biopharmaceuticals and Westlake University Launch Universal Influenza Vaccine Collaboration","datePublished":"2026-04-14T12:34:29+00:00","dateModified":"2026-04-14T12:34:30+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63115"},"wordCount":465,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=63115#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1402-1.webp","keywords":["Olymvax Biopharmaceuticals","SHA: 688319","Vaccine"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63115#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63115","url":"https:\/\/flcube.com\/?p=63115","name":"Olymvax Biopharmaceuticals and Westlake University Launch Universal Influenza Vaccine Collaboration - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=63115#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=63115#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1402-1.webp","datePublished":"2026-04-14T12:34:29+00:00","dateModified":"2026-04-14T12:34:30+00:00","description":"Olymvax Biopharmaceuticals Inc. (SHA: 688319), the Chengdu-based vaccine specialist, announced a strategic partnership agreement with Westlake University, China's first modern private research-oriented university, to jointly advance early-stage R&D of a broad-spectrum (universal) influenza vaccine. The collaboration integrates Westlake's basic scientific research capabilities with Olymvax's mature vaccine industrialization experience.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63115#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63115"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=63115#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1402-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1402-1.webp","width":1080,"height":608,"caption":"Olymvax Biopharmaceuticals and Westlake University Launch Universal Influenza Vaccine Collaboration"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63115#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Olymvax Biopharmaceuticals and Westlake University Launch Universal Influenza Vaccine Collaboration"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1402-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63115","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63115"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63115\/revisions"}],"predecessor-version":[{"id":63118,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63115\/revisions\/63118"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/63116"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63115"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63115"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63115"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}